Journal article
Tumor necrosis factor gene variation predicts hippocampus volume in healthy individuals
BT Baune, C Konrad, D Grotegerd, T Suslow, P Ohrmann, J Bauer, V Arolt, W Heindel, K Domschke, S Schöning, AV Rauch, C Sehlmeyer, H Kugel, U Dannlowski
Biological Psychiatry | ELSEVIER SCIENCE INC | Published : 2012
Abstract
Background: Cytokines such as tumor necrosis factor (TNF) α have been implicated in neurodegeneration relevant to various neuropsychiatric disorders. Little is known about the genetic predisposition to neurodegenerative properties of cytokine genes on brain function and on hippocampus (HC) function in particular. In this study we investigate the neurodegenerative role of TNF polymorphisms on brain morphology in healthy individuals. Methods: Voxel-based morphometry was used in a large sample of healthy individuals (n = 303) to analyze the associations between genetic variants of TNF (rs1800629; rs361525) and brain morphology (gray matter concentration). Results: In a region of interest analys..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The study was supported by grants from Innovative Medizinische Forschung of the Medical Faculty of Munster (DA120309, DA111107, and DA211012 to UD), Rolf-Dierichs-Stiftung (ZUW80037 to UD), and Interdisziplinares Zentrum fur Klinische Forschung of the Medical Faculty of Munster. Professor Volker Arolt, M. D., Ph.D., is a member of advisory boards and/or gave presentations for the following companies: Astra-Zeneca, Janssen-Organon, Lilly, Lundbeck, Servier, Pfizer, and Wyeth. He chairs the committee for the "Wyeth Research Award Depression and Anxiety," now the DGPPN/Pfizer "Clinical Neuroscience Award." Professor Bernhard T. Baune, M. D., P. h. D., M. P. H., is a member of advisory boards and/or gave presentations for the following companies: AstraZeneca, Lundbeck, Pfizer, Servier, and Wyeth. He receives funding from the National Health and Medical Research Council Australia. Professor Katharina Domschke, M. A., M. D., Ph.D., is on the speakers' board of Pfizer, Lilly, and Bristol-Myers Squibb; has been a consultant for Johnson and Johnson, and has received funding by Astra Zeneca. These affiliations have no relevance to the work covered in the manuscript. All other authors report no biomedical financial interests or potential conflicts of interest.